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Abstract
Background: Treatment of pulmonary recurrence from colorectal cancer involving the main bronchus usually
entails palliation using interventional bronchoscopy, because the prognosis is generally very poor. Surgical
experience has clarified that in this setting pneumonectomy should only be performed in carefully selected patients
showing favorable prognostic profiles (defined by low carcinoembryonic antigen serum levels pre-thoracotomy),
solitary and completely resectable pulmonary metastasis, and long disease-free intervals. In the few long-term
survivors after pneumonectomy for late-recurrent colorectal cancer, the disease has a relatively indolent metastatic
course and genetic and epigenetic profiling may provide further insight regarding tumor evolution.
Case presentation: We describe a rare case of late hilar-endobronchial and lymph nodal recurrence of rectal
cancer, sequential to hepatic metastasectomy, that we successfully treated with pneumonectomy and
chemotherapy (leucovorin, 5-fluorouracil and oxaliplatin regimen); the patient achieved 7-year relapse-free survival
after lung metastasectomy and 24-year overall survival after primary rectal cancer resection. To our knowledge, this
is the longest survival reported after sequential liver resection and pneumonectomy for recurrent colorectal cancer.
In our case the primary rectal cancer and its recurrences showed identical immunohistochemical patterns. The
primary rectal cancer and the matched metastases (hepatic, pulmonary and lymph nodal) demonstrated no KRAS,
NRAS, BRAF and PIK3CA mutations, a microsatellite stable phenotype, and no tumor protein p53 alterations or
recurrent copy number alterations on chromosome 8. High genetic concordances between the paired primary
tumor and metastases suggest that the key tumor biological traits remained relatively conserved in the three
metastatic sites. Minor differences in gene specific hypermethylation were observed between the primary tumor
and lung and nodal metastases. These differences suggest that epigenetic mechanisms may be causally involved in
the microenvironmental regulation of cancer metastasis.
Conclusion: The exceptionally long survival of the patient in our case study involving favorable clinical features was
related to an excellent response to surgery and adjuvant chemotherapy; however, genetic or epigenetic factors that
remain unidentified cannot be excluded as contributory factors. Our findings support the concept of a common
clonal origin of the primary cancer and synchronous and late metastases, and suggest that aberrant DNA
methylation may regulate tumor dormancy mechanisms.
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Background
The occurrence of sequential or concurrent liver and
lung metastases after resection of colorectal cancer
(CRC), with the exception of carefully selected patients,
has traditionally been associated with poor long-term
outcome [1–3]. For lung recurrence involving the prox-
imal bronchi, the role of radical surgical cure remains
uncertain, while palliation can be achieved by interven-
tional bronchoscopy [4]. Because there have been few
reports regarding patients with a history of hepatic
metastasectomy for CRC who underwent pneumonec-
tomy for the cure of a subsequent metastasis to the lung
hilum [5–7], the clinical profile of patients who might
benefit from pneumonectomy in this setting remains un-
defined [8, 9]. Moreover, metastases are seldom excised
or biopsied in advanced-stage patients and there have
been few studies that have focused on paired analysis of
primary tumors and metastases for the purpose of tra-
cing the tumor lineage during metastasization [10].
Here, we present a rare case of solitary hilar recur-
rence of rectal cancer with endobronchial extension, di-
agnosed at 17 years after primary rectal tumor resection
and hepatic metastasectomy; the patient was treated
with pneumonectomy and chemotherapy and has
achieved an overall survival time of 24 years. In this pa-
tient, we performed a comprehensive study of the histo-
logic, immunohistochemical, genetic and epigenetic
profiles of the primary tumor and of its metastases to
the liver, lung and lymph nodes.
Case presentation
In 1990, a 40-year-old male underwent anterior resec-
tion of rectal adenocarcinoma (Dukes B2; preoperative
carcinoembryonic antigen (CEA) serum level: 35 ng/
mL), that was diagnosed synchronously with a 9-cm me-
tastasis in liver segments V-VIII. After postoperative 5-
fluorouracil based chemotherapy, the CEA serum level
was slightly decreased (22 ng/mL); liver metastasis was
markedly downsized and was radically resected. Follow-
up revealed no evidence of residual disease until 2002;
follow-up was then intentionally interrupted because the
patient was considered to be free of disease. On March
2007, the patient developed dyspnea and cough, and a
chest computed tomography (CT) scan revealed a 5-cm
right hilar mass bulging into the main bronchus and in-
filtrating the upper lobe (Figs. 1 and 2a). Bronchoscopy
demonstrated a neoplastic growth that was obstructing
the right main bronchus 2 cm distal to the carina; biopsy
revealed moderately differentiated adenocarcinoma,
compatible with rectal cancer recurrence. Colonoscopy
and CT of the abdomen and pelvis showed no other evi-
dence of neoplastic disease, and the CEA serum level
was normal (1 ng/mL). On April 2007, the patient was
aged 57 years and was fit for major thoracic surgery. He
was treated by means of right pneumonectomy and re-
gional lymphadenectomy to obtain complete resection
(Fig. 2b). Histology of the excised lung metastasis
(Fig. 2c) revealed an adenocarcinomatous proliferation
with morphological features overlapping those of pri-
mary rectal cancer and of previously resected hepatic
metastasis. The primary cancer and all of the metastatic
sites were characterized by extensive complex tubular
gland formation with sparse centroglandular necrotic
foci. Nuclei were moderately or highly atypical, elongated
and stratified. The mitotic index ranged from 17 (in rectal
cancer) to 24 × 10 high power fields (in metastatic sites).
A mild peritumoral lymphocytic infiltrate (cluster of dif-
ferentiation 3 positive) was present. Budding was absent
and there was no lymphovascular invasion. The immuno-
phenotype included caudal-type homeobox protein 2 and
cytokeratin (CK) 20 (CK 20) positivity (Fig. 2c, inset),
whereas thyroid transcription factor-1 and CK 7 were
negative. The main bronchus resection margin was
tumor-free. Of the 18 lymph nodes excised, 4 (all peri-
bronchial) were metastatic. The early postoperative
course was complicated by empyema that was success-
fully treated with antibiotics and drainage. Follow-up
with CT scans of the chest and abdomen at 6 months
after pneumonectomy revealed enlarged left supraclavi-
cular lymph nodes (Fig. 2d). Biopsy of the latter revealed
a metastatic adenocarcinomatous growth with a high
mitotic index (14 × 10 high-power fields) and a morpho-
logical and immunohistochemical profile identical to
that previously described (Fig. 2e). There were no other
signs of relapse. Systemic chemotherapy (leucovorin, 5-
fluorouracil and oxaliplatin regimen) was then initiated
and continued until July 2008, resulting in complete
Fig. 1 Chest Computed Tomography (CT). Chest CT scan coronal
view showing 5-cm right hilar mass bulging into the main bronchus
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clinical remission. Subsequent follow-up with semi-
annual assessments of CEA level and total body CT
and/or a positron emission tomography scans revealed
no evidence of recurrence. At the last examination, in
February 2015, the patient was relapse-free and enjoyed
a good quality of life, at 7 years after pneumonectomy
for lung metastasis and at 24 years after rectal cancer
resection. Genetic and epigenetic profiles of the primary
tumor and the three matched metastases (pulmonary,
hepatic and lymph nodal) were assessed to verify the
clonal origin of the four tumor samples and to
characterize key biological traits during the tumor evo-
lution. Tables 1 and 2 summarize the molecular results.
Methylation specific-multiplex ligation dependent probe
amplification (MS-MLPA) was performed by using the
ME001 MS-MLPA tumor suppressor-1 kit and the
ME002 MS-MLPA tumor suppressor-2 Kit (MRC-Hol-
land, Amsterdam, The Netherlands) to simultaneously
analyze the methylation status of 33 tumor suppressor
genes and copy number alterations (CNA) of 53 genes
[11]. The primary rectal carcinoma showed a high fre-
quency of CNAs at multiple chromosome regions sug-
gesting an unstable karyotype in this tumor. Clonal
CNAs including chromosome gains at 7q, 9pq, 11pq,
13q, 19p and 20q were recurrent in the primary tumor
and in the matched metastases, demonstrating a common
origin of the four tumor samples (Table 1). Similarly,
clonal gene specific hypermethylation was observed at
adenomatous polyposis coli (APC) and cadherin 13
(CDH13) loci, while additional hypermethylated genes,
namely WT1, DAPK1, CHFR, PAX5 and GATA5, were
found in the lung and in supraclavicular lymph node me-
tastases (Table 2). Microsatellite instability (MSI) analysis,
carried out using a pentaplex panel of monomorphic
mononucleotide repeats (BAT25, BAT26, NR-21, NR-22
and NR-24) as previously reported [12], demonstrated the
Fig. 2 Chest CT details, histological and immunohystochemical studies. a Chest CT-scan axial view (lung window) showing a right hilar mass and
post-obstructive collapse in the upper lobe anterior segment. b Close view of right pneumonectomy bronchial section margin (arrows); the main
bronchus is obstructed by a polypoid tumor. c Lung metastatic adenocarcinomatous proliferation (hematoxylin & eosin staining, original
magnification × 400); inset shows CDX-2 immunohistochemical staining (left), and CK20 positivity (right). d Chest CT-scan six months after right
pneumonectomy, demonstrating enlarged left supraclavicular lymph nodes (arrow). e Lymph node metastasis with morphological features
similar to Fig. 2c (hematoxylin & eosin staining, original magnification × 400); inset shows CDX-2 positivity
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absence of MSI in all tumor samples. The Maldi-TOF
mass spectrometry platform and the myriapod colon sta-
tus kit (Diatech Pharmacogenetics, Jesi, Italy) were used to
profile the patient’s four tumor samples, analyzing the 216
common hot-spot cancer mutations in the four major on-
cogenes involved in CRC pathogenesis (KRAS, BRAF,
PIK3CA and NRAS). This analysis demonstrated no gene
mutation in the primary rectal adenocarcinoma, and inter-
estingly this genetic profile remained relatively well pre-
served in the three metastatic sites.
Discussion
The decision regarding surgical treatment is critical
when an isolated lung metastasis can only be radically
resected using pneumonectomy, as was true in the
present case. Following sequential surgical resection of
the hepatic and pulmonary recurrences from CRC, the
following factors are predictive of long-term survival and
can help in addressing surgical strategies: 1) low CEA
serum level pre-thoracotomy [7]; 2) solitary pulmonary
recurrence after a long disease-free interval [3, 7]; 3)
complete resection of lung recurrence after hepatic
metastasectomy [5]; and 4) responsiveness to chemo-
therapy [2, 5]. Clearly, aggressive treatment of sequen-
tial recurrences can only be beneficial for carefully
selected patients. Accordingly, the management of a
hilar-endobronchial recurrence from CRC should be
individualized after considering all endoscopic and sur-
gical options. In the case presented here, potentially
radical resection in a fit-for-surgery patient with a
long-term clinical history suggestive of a relatively in-
dolent rectal cancer (associated with a normal CEA
serum level) lead to the indication of pneumonectomy
for the treatment of an isolated recurrence of rectal
cancer involving the main bronchus. We did not per-
form right upper lobe sleeve resection because at intra-
operative evaluation this procedure was inadequate in
achieving local radical excision of the pulmonary me-
tastasis and lymph nodes. To our knowledge, the sur-
vival time of our case is the longest so far reported
after sequential liver resection and pneumonectomy
for recurrent CRC [7].
Extensive genetic and epigenetic profiling of the primary
rectal adenocarcinoma allowed the characterization of the
key biological traits of the tumor and comparison with the
recent results of CRC molecular characterization [13]. Ac-
cording to this comprehensive classification, the primary
cancer reported in the present case may probably be des-
ignated as a non-hypermutated tumor, because we did not
find any of the hot-spot gene mutations commonly ob-
served in CRC. Moreover, it did not exhibit the presence
of MSI or a cytosine-phospho-guanine island methylator
Table 2 Genetic and epigenetic alterations in the primary tumor and matched metastases
Tumor sample Gene hypermethylationa MSIb status BRAF KRAS NRAS PIK3CA
Primary rectal cancer APC; CDH13; WT1 MSS - - - -
Hepatic metastasis APC; CDH13 MSS - - - -
Lung metastasis APC; CDH13; WT1; DAPK1; CHFR; GATA5 MSS - - - -
Lymph nodal metastasis APC; CDH13; PAX5; DAPK1; CHFR; GATA5 MSS - - - -
aList of hypermethylated genes; clonal gene hypermethylations are shown in bold font. APC adenomatous polyposis coli, CDH13 cadherin 13
bMSI microsatellite instability. MSS: microsatellite stable. -: absence of BRAF, KRAS, NRAS, PIK3CA mutations assayed using the myriapod colon status panel
Table 1 Copy number alterations (CNAs) observed in the primary tumor and in the matched metastases
Chromosomal position Primary rectal carcinoma Hepatic metastasis Lung metastasis Lymph nodal metastasis
1p + + - +
2p + + - +
3p + + - -
7q + + + +
9p + + + +
11p + + + +
11q + + + +
12p + + - -
12q + + - -
13q + + + +
19p + + + +
20q + + + +
+: presence of CNA; -: absence of CNA
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phenotype. As expected, this non-hypermutated tumor
had a large number of CNAs including several previously
well-defined chromosomal and sub-chromosomal changes
in CRC, such as gains of 7q, 11p, 13q and 20q. Remark-
ably, the tumor did not exhibit alterations in tumor pro-
tein p53 (TP53) or recurrent CNAs on chromosome 8
that are the most frequent events in highly aggressive can-
cers exhibiting copy number genomic instability [13]. Fi-
nally, a key feature of the primary rectal adenocarcinoma
was APC and CDH13 methylation, suggesting an aberrant
activation of the wingless signaling pathway that is consid-
ered a nearly ubiquitous event in CRC [13].
Comparison between the primary cancer and the
matched metastases demonstrated high genetic con-
cordances and minor differences among samples; this
was in agreement with the current literature, support-
ing the concept that concordance is dominant during
the metastatic process and reflects the common clonal
origin of primary cancer and metastases [10]. Many
studies have suggested that the primary tumor site is
also the location where cancer cells obtain their meta-
static potential [10]. They reach secondary organs
through the circulatory system, and display dormancy,
apoptosis or proliferation. According to this hypothesis,
when the dormant cells receive some specific signals, me-
tastasis will occur [14]. This model is supported by the
similarities in gene expression signatures observed be-
tween metastases and their corresponding primary tumors
in several different types of cancer including breast, pan-
creatic, CRC and prostate [15]. Recent evidence has sug-
gested that epigenetic mechanisms, such as aberrant DNA
methylation and microRNAs, may regulate the long-term
commitment of disseminated tumor cells to quiescence
while retaining growth potential [15, 16]. In the case re-
ported here, the different methylation profiles of lung and
lymph nodal metastases, as compared with the primary
cancer and the liver metastasis, are consistent with this
hypothesis. The unexpected finding of a normal CEA level
at the time of lung recurrence and subsequent supraclavi-
cular lymph node recurrence, and the fact that the genetic
signature of the primary tumor and matched metastases
remained stable, could be explained by epigenetic mecha-
nisms. The latter are well known to modulate the expres-
sion of adhesion molecules during the metastatic process
[17, 18]. Interestingly, the sensitivity of the CEA test has
been shown to depend on the site of CRC metastasis; in a
large multicenter study, the test was reported to be grossly
insensitive for solitary lung recurrences, because these
were detectable using CEA in only 15 % of cases [19].
Conclusions
Cancer survival is in part related to the natural biology
of slow-growing tumors. However, here we presented
the case of a patient with pulmonary and lymph nodal
metastases that occurred many years after primary tumor
removal; these metastases exhibited morphological fea-
tures of aggressive growth, including marked atypia, high
mitotic index and tumor necrosis. The extensive genetic
and epigenetic profiling of the primary rectal cancer and
of the matched metastases demonstrated the absence of
KRAS, NRAS, BRAF and PIK3CA mutations, a microsatel-
lite stable phenotype; in addition, there were no TP53 al-
terations and no recurrent CNAs on chromosome 8. Our
findings support the concept of the common clonal origin
of the primary cancer and of the synchronous and late
metastases, suggesting that the key tumor biological traits
remained quite conserved and that epigenetic mecha-
nisms may be causally involved in the microenvironmental
regulation of cancer metastasis. The exceptionally long
survival time of the current case was probably related to
an excellent response to surgery and adjuvant chemother-
apy; however, it might also be associated with yet to be
identified genetic or epigenetic factors involved in the
change from dormancy to the activation of metastasis.
Our data are preliminary and need to be confirmed,
but they suggest the importance of future genome-scale
analyses of methylomes and microRNA expression in
comparing primary tumors and matched metastases.
Consent
Written informed consent was obtained from the patient
for publication of this case report and any accompanying
images. A copy of the written consent is available for
review by the Editor of this journal.
Abbreviations
CRC: Colorectal cancer; CT: Computed tomography; CNA: Copy number
alterations; MSI: Microsatellite instability; MSS: Microsatellite stable;
CEA: Carcinoembryonic antigen; CK: Cytokeratin; MS-MLPA: Methylation
specific-multiplex ligation dependent probe amplification; APC: Adenomatous
polyposis coli; CDH13: Cadherin 13; TP53: Tumor protein p53.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
AI, LD and DF conceived of the study and participated in its design and
coordination. NR, EN and MC participated in patient care, reviewed the
literature, prepared the figures and helped to draft the manuscript. LC and
CR carried out the immunohistochemical studies. FS and DF interpreted the
genetic studies and helped to draft the manuscript. All of the authors read
and approved the final manuscript.
Acknowledgements
The authors wish to acknowledge the valuable contribution of Dr Mauro Bandera
regarding the patients’ continuing care and follow-up. We also gratefully
acknowledge the assistance of Mr Timothy Sampson in editing the manuscript.
This study has been supported by the Epigenomics Flagship Project—EPIGEN (to
DF), and by a grant from the Italian Ministry of Health (Project no. 08934412).
Author details
1Center for Thoracic Surgery, Department of Surgical and Morphological
Sciences, University of Insubria, Ospedale di Circolo, Via Guicciardini, 9, Varese
21100, Italy. 2Section of Anatomic Pathology, Department of Surgical and
Morphological Sciences, University of Insubria, Ospedale di Circolo, Via O.
Rossi, 9, Varese 21100, Italy.
Imperatori et al. BMC Cancer  (2015) 15:567 Page 5 of 6
Received: 2 March 2015 Accepted: 27 July 2015
References
1. Rees M, Tekkis PP, Welsh FK, O’Rourke T, John TG. Evaluation of long-term
survival after hepatic resection for metastatic colorectal cancer: a
multifactorial model of 929 patients. Ann Surg. 2008;247:125–35.
2. Sourrouille I, Mordant P, Maggiori L, Dokmak S, Lesèche G, Panis Y, et al.
Long-term survival after hepatic and pulmonary resection of colorectal
cancer metastases. J Surg Oncol. 2013;108:220–4.
3. Miller G, Biernacki P, Kemeny NE, Gonen M, Downey R, Jarnagin WR, et al.
Outcomes after resection of synchronous or metachronous hepatic and
pulmonary colorectal metastases. J Am Coll Surg. 2007;205:231–8.
4. Fournel C, Bertoletti L, Nguyen B, Vergnon JM. Endobronchial metastases
from colorectal cancers: natural history and role of interventional
bronchoscopy. Respiration. 2009;77:63–9.
5. Neeff H, Hörth W, Makowiec F, Fischer E, Imdahl A, Hopt UT, et al. Outcome
after resection of hepatic and pulmonary metastases of colorectal cancer.
J Gastrointest Surg. 2009;13:1813–20.
6. Shah SA, Haddad R, Al-Sukhni W, Kim RD, Greig PD, Grant DR, et al. Surgical
resection of hepatic and pulmonary metastases from colorectal carcinoma.
J Am Coll Surg. 2006;202:468–75.
7. Regnard JF, Grunenwald D, Spaggiari L, Girard P, Elias D, Ducreux M, et al.
Surgical treatment of hepatic and pulmonary metastases from colorectal
cancers. Ann Thorac Surg. 1998;66:218–9.
8. Pfannschmidt J, Hoffmann H, Dienemann H. Reported outcome factors for
pulmonary resection in metastatic colorectal cancer. J Thorac Oncol.
2010;5:S172–8.
9. Rotolo N, De Monte L, Imperatori A, Dominioni L. Pulmonary resections of
single metastases from colorectal cancer. Surg Oncol. 2007;16:S141–4.
10. Gao D, Li S. Biological resonance for cancer metastasis, a new hypothesis
based on comparisons between primary cancers and metastases. Cancer
Microenviron. 2013;6:213–30.
11. Furlan D, Sahnane N, Bernasconi B, Frattini M, Tibiletti MG, Molinari F, et al.
APC alterations are frequently involved in the pathogenesis of acinar cell
carcinoma of the pancreas, mainly through gene loss and promoter
hypermethylation. Virchows Arch. 2014;464:553–64.
12. Furlan D, Carnevali IW, Bernasconi B, Sahnane N, Milani K, Cerutti R, et al.
Hierarchical clustering analysis of pathologic and molecular data identifies
prognostically and biologically distinct groups of colorectal carcinomas.
Mod Pathol. 2011;24:126–37.
13. Muzny DM, Bainbridge MN, Chang K, Dinh HH, Drummond JA, Fowler G, et
al. Comprehensive molecular characterization of human colon and rectal
cancer. Nature. 2012;487:330–7.
14. Rotolo N, Dominioni L, De Monte L, Conti V, La Rosa S, Imperatori A.
Metastasis at a tracheostomy site as the presenting sign of late recurrent
breast cancer. Head Neck. 2013;35:E359–62.
15. Zhang Y, Yang P, Wang XF. Microenvironmental regulation of cancer
metastasis by miRNAs. Trends Cell Biol. 2014;24:153–60.
16. Bedi U, Mishra VK, Wasilewski D, Scheel C, Johnsen SA. Epigenetic plasticity:
a central regulator of epithelial-to-mesenchymal transition in cancer.
Oncotarget. 2014;5:2016–29.
17. Cock-Rada A, Weitzman JB. The methylation landscape of tumour
metastasis. Biol Cell. 2013;105:73–90.
18. Hammarstrom S. The carcinoembryonic antigen (CEA) family: structure
suggested functions and expression in normal and malignant tissues. Semin
Cancer Biol. 1999;9:67–91.
19. Moertel CG, Fleming TR, MacDonald JS, Haller DG, Laurie JA, Tangen C. An
evaluation of the carcinoembryonic antigen (CEA) test for monitoring
patients with resected colon cancer. JAMA. 1993;270:943–7.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Imperatori et al. BMC Cancer  (2015) 15:567 Page 6 of 6
